Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Sponsor
Henan Cancer Hospital
Study ID
NCT03397199
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib + S-1 — DRUG
    Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.

Study Details

The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.

Key Dates

Start date
Jan 9, 2018
Status verified
Apr 2020
Primary completion
Oct 31, 2020
Completion
Mar 31, 2021

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib + S-1
    Apatinib + S-1

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: up to 2 year ]

Central Contacts

Related Studies